LOGO
LOGO

Will BCTX Get A Boost From Upcoming Phase 3 Breast Cancer Trial Data?

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
scientist 09012026 lt

BriaCell Therapeutics Corp. (BCTX), a clinical-stage biotechnology company developing novel immunotherapies, has a key clinical trial milestone this year as it advances potential treatments for patients with metastatic breast cancer facing urgent medical needs.

Breast cancer is the most common cancer in women in the United States, with more than 40,000 deaths per year in the United States, according to the latest data from the American Cancer Society.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - Jun 08-12, 2026

June 12, 2026 17:14 ET
Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.

RELATED NEWS